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ABSTRACT
Objective: The chemotherapy response score (CRS) system based on histopathological 
examination has been recently proposed for tubo-ovarian high-grade serous carcinoma 
(HGSC) to assess response to neoadjuvant chemotherapy (NAC). This study was aimed at 
validating the CRS system in an external cohort of tubo-ovarian HGSC patients.
Methods: This study included 110 tubo-ovarian HGSC patients who underwent NAC followed 
by interval debulking surgery. The 3-tiered CRS of the omental and adnexal tissue sections 
was determined by 3 independent pathologists. Differences in patient outcomes according to 
CRS were analyzed.
Results: The CRS system was highly reproducible among the 3 pathologists. Fleiss' kappa 
value and Kendall's coefficient of concordance for the omental CRS were 0.656 and 0.669, 
respectively. The omental CRS significantly predicted progression-free survival (PFS). The 
median PFS of patients whose tumors exhibited the omental CRS 1–2 (15 months) was 
significantly shorter than that of patients with an omental CRS of 3 (19 months; p=0.016). 
In addition, after adjusting for age, stage, and debulking status, the omental CRS was an 
independent prognostic factor for PFS of tubo-ovarian HGSC patients who were treated with 
NAC (adjusted hazard ratio [HR]=1.74; 95% confidence interval [CI]=1.05–2.87).
Conclusion: The CRS system for assessing NAC response was a reproducible prognostic tool 
in our cohort. The application of the CRS system after NAC can improve survival estimation 
in HGSC patients.
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INTRODUCTION
Ovarian cancer is a lethal gynecologic cancer, and its incidence and mortality are increasing 
in the Korea [1,2]. The vast majority of ovarian cancer patients present with advanced-stage 
disease. Primary debulking surgery followed by postoperative platinum-based chemotherapy 
is the cornerstone of management for advanced ovarian cancer. Two randomized controlled 
phase III trials showed that interval debulking surgery (IDS) produces progression-free 
survival (PFS) and overall survival (OS) equivalent to those of primary debulking surgery. As 
a result, there is a trend towards neoadjuvant chemotherapy (NAC) followed by IDS [3,4] for 
the treatment of advanced high-grade serous carcinoma (HGSC).
To date, there is no uniform consensus regarding the prognostic value of the 
histopathological grading system to assess NAC response on tumor tissue obtained during 
IDS. Recently, Böhm et al. [5] proposed a simple and reproducible scoring system for grading 
the response of tubo-ovarian HGSC to NAC based on histopathological examination of IDS 
specimens. They reported that the 3-tiered chemotherapy response score (CRS) of omental 
tissue sections showed a significant association with PFS and OS in their validation cohort, 
indicating promise in refining the assessment of NAC response in tubo-ovarian HGSCs 
[5]. However, it is warranted to test whether the good performance of the CRS system is 
reproducible in diverse clinical settings such as those exhibiting differences in the selection 
criteria for NAC, extent of surgery, chemotherapy policies, or experience of pathologists. 
The aim of this study was to validate the CRS system for assessing treatment response in an 
external cohort of HGSC patients treated with NAC.
MATERIALS AND METHODS
1. Study population
From 2006 to 2014, electronic medical records of patients with tubo-ovarian or peritoneal 
HGSC who underwent NAC and subsequent IDS in the Department of Obstetrics and 
Gynecology, Severance Hospital, Yonsei University College of Medicine were retrospectively 
analyzed. The same inclusion and exclusion criteria as those reported by Böhm et al. [5] were 
applied. In brief, the inclusion criteria were 1) histopathologically confirmed International 
Federation of Gynecology and Obstetrics (FIGO) stage IIIC–IV HGSC patients; 2) ovarian, 
tubal, or primary peritoneal HGSC; and 3) IDS. This study was reviewed and approved by the 
Institutional Review Board at Severance Hospital, Yonsei University Health System, Seoul, 
Korea (IRB No. 4-2015-1158).
Regarding primary treatment strategy, the selection criteria for NAC were not described in 
the study of Böhm et al. [5]. In this study, we applied 2 gate models for primary treatment 
strategies in advanced HGSCs. All patients had preoperative computed tomography 
(CT) and positron emission tomography (PET)/CT. NAC was performed for those who 1) 
developed pulmonary and/or hepatic parenchymal metastasis in imaging analyses; 2) were 
medically inoperable; and 3) were judged unsuitable for optimal debulking surgery due to 
high tumor burden based on the Fagotti's score (scored over 8) [6]. All surgical procedures 
were performed by a gynecologic oncology team comprising 5 experienced gynecologic 
surgeons. IDS was performed via long midline laparotomy, hysterectomy, bilateral 
salpingo-oophorectomy, omentectomy, and pelvic and paraaortic lymphadenectomy, 
with or without various radical surgeries (e.g., bowel resection, diaphragmatic resection, 
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and peritonectomy). After surgery, patients received 3–6 cycles of postoperative adjuvant 
chemotherapy (POAC). Both NAC and POAC were routinely given as a combination of 
carboplatin and taxane. All therapeutic procedures were provided according to the National 
Comprehensive Cancer Network Clinical Practice Guidelines in Oncology [7].
2. Pathology review
The resected specimens were formalin-fixed and paraffin-embedded according to standard 
procedures and stained with hematoxylin and eosin (H&E) in the Department of Pathology, 
Severance Hospital, Yonsei University College of Medicine. All available H&E-stained slides 
obtained from IDS specimens were reviewed by an experienced gynecologic pathologist 
(H.S.K.). The slide with the most viable tumor and/or the least chemotherapy response was 
selected from each of 3 sites: omentum, right adnexa, and left adnexa. Three pathologists 
(H.S.K., H.M.K., and C.K.P.) independently scored each slide according to the 3-tiered CRS 
system proposed by Böhm et al. [5]. In brief, CRS 1 indicates no or minimal tumor response; 
mainly viable tumor with no or minimal regression-associated fibroinflammatory changes, 
limited to a few foci; and cases in which it is difficult to decide between regression and 
tumor-associated desmoplasia or inflammatory cell infiltration (Fig. 1A). CRS 2 indicates 
appreciable tumor response amid viable tumor that is readily identifiable; multifocal or 
diffuse regression-associated fibroinflammatory changes with viable tumor in sheets, 
streaks, or nodules; and extensive regression-associated fibroinflammatory changes with 
multifocal residual tumor, which is easily identifiable (Fig. 1B). CRS 3 indicates complete 
or near-complete response with no residual tumor; minimal irregularly scattered tumor 
foci seen as individual cells, cell groups, or nodules up to 2 mm maximum size; mainly 
regression-associated fibroinflammatory changes; and no or very little residual tumor in the 
complete absence of any inflammatory response (Fig. 1C).
Each pathologist was blinded to the results of other pathologists. Following submission 
of independent scores for reproducibility analysis, all cases in which the score was not 
unanimous were reviewed jointly using a multi-headed microscope. The agreed upon 
consensus score was used for outcome analysis.
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A B C
Fig. 1. Examples of histopathological features of tumor regression after NAC corresponding to CRS 1 to 3. CRS 1: no or minimal tumor response (A). CRS 2: 
appreciable tumor response amid viable, readily identifiable tumor (B). CRS 3: complete or near-complete response with no or minimally residual tumor (C). 
CRS, chemotherapy response score; NAC, neoadjuvant chemotherapy.
3. Statistical analysis
Fleiss' kappa statistics and Kendall's coefficient of concordance were used to assess levels of 
agreement among the pathologists. Survival outcomes according to the CRS were analyzed. 
The PFS and OS curves were drawn using the Kaplan-Meier method, and the curves were 
compared using a log-rank test. Adjusted hazard ratios (HRs) for PFS and OS were estimated 
with a Cox proportional hazards model. In addition, the performance of CRS was evaluated 
using the concordance index (c-index). A bootstrap method (1,000 repetitions) was used 
to obtain more unbiased estimates of the c-index. Statistical significance was defined as a 
p<0.050. All statistical analyses were performed using STATA ver. 12.0 (StataCorp LP, College 
Station, TX, USA).
RESULTS
1. Baseline characteristics
We found 115 stage IIIC–IV ovarian cancer patients who underwent NAC followed by IDS 
in our institutional databases. One hundred and ten (95.7%) patients met the inclusion 
criteria. Three (2.6%) patients with ovarian clear cell carcinoma and 2 (1.7%) with 
carcinosarcoma were excluded. The baseline characteristics of the patients are summarized 
in Table 1. The median age of the patients was 57 years (range, 27–80 years). All patients had 
histopathologically confirmed HGSC and underwent platinum/taxane-based chemotherapy.
2. Interobserver reproducibility of 3-tiered CRS system
The interobserver reproducibility of the 3-tiered CRS system was assessed. The omental 
CRS showed high reproducibility among the 3 independent pathologists (Fleiss' kappa 
value=0.656; Kendall's coefficient of concordance=0.669; absolute agreement=71.7%). 
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Table 1. Baseline characteristics
Characteristics No. of patients (%)
Age (yr)
Median 57
Range 27–80
Primary site
Tubo-ovarian 99 (90.0)
Peritoneal 11 (10.0)
Histological type
HGSC 110 (100.0)
FIGO stage
IIIC 47 (42.7)
IV 63 (57.3)
Residual disease <1 cm 52 (47.3)
Residual disease >1 cm 6 (5.5)
Not applicable 14 (12.7)
Regimen of NAC
Taxane+carboplatin 110 (100.0)
Cycles of NAC
3–4 97 (88.2)
>4 13 (11.8)
Total cycles of chemotherapy
<6 6 (5.5)
6 37 (33.6)
7–9 55 (50.0)
10–12 12 (10.9)
FIGO, International Federation of Gynecology and Obstetrics; HGSC, high-grade serous carcinoma; NAC, 
neoadjuvant chemotherapy.
In addition, we observed comparable reproducibility of the adnexal CRS with that of the 
omental CRS (Table 2). These findings were not consistent with those from previous data 
showing that the adnexal CRS showed inferior reproducibility to the omental CRS [5].
3. Association of CRS with patient survival
The distribution of CRS in our cohort (CRS 1, 5.5%; CRS 2, 51.8%; CRS 3, 42.7%) was 
significantly different from that of Böhm et al. [5]'s validation cohort (CRS 1, 0%; CRS 2, 
70.0%; CRS 3, 30.0%; p<0.050). In our cohort, the omental CRS displayed a significant 
prognostic value for PFS between CRS 1–2 and CRS 3; the median PFS of patients with CRS 
1–2 and CRS 3 tumors was 14.5 and 18.6 months, respectively (p=0.016; Fig. 2A). There were 
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Table 2. Fleiss' kappa value, Kendall's coefficient of concordance, absolute agreement, and p-value for 3-tiered 
CRS system in external validation cohort
Parameters Right adnexa Left adnexa Omentum
Fleiss' kappa value 0.697 0.707 0.656
Kendall's coefficient of concordance 0.609 0.647 0.669
Absolute agreement (%) 76.6 76.7 71.7
p-value <0.001 <0.001 <0.001
CRS, chemotherapy response score.
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Fig. 2. PFS and OS according to the 3-tiered CRS system in the omentum of tubo-ovarian HGSC patients receiving NAC. PFS according to the omental CRS (CRS 
1–2 vs. CRS 3) (A). PFS according to omental CRS (CRS 1 vs. CRS 2 vs. CRS 3) (B). OS according to omental CRS (CRS 1–2 vs. CRS 3) (C). 
CRS, chemotherapy response score; HGSC, high-grade serous carcinoma; NAC, neoadjuvant chemotherapy; OS, overall survival; PFS, progression-free survival.
significant differences in PFS between patients with CRS 1 and CRS 2 tumors (p<0.001) and 
between those with CRS 2 and CRS 3 tumors (p=0.046), respectively (Fig. 2B). Unlike Böhm 
et al. [5]'s validation cohort, which exhibited no significant difference in survival between 
CRS 1 and CRS 2 diseases, we did observe a significant difference between those groups. 
When adjusted for age, stage, and debulking status, the CRS was an independent prognostic 
factor for PFS (CRS 1–2 vs. CRS 3; adjusted HR=1.74; 95% confidence interval [CI]=1.05–
2.87). A log-rank test revealed no significant difference in OS between CRS 1–2 and CRS 3 
(p=0.902; Fig. 2C). With interval validation using the bootstrap method (1,000 runs), the 
c-index for the Cox model was 0.725 (95% CI=0.650–0.793) for recurrence.
4. Association of CRS with debulking status and platinum resistance
No gross residual disease after IDS was achieved in 23.8% of patients with CRS 1–2, whereas 
48.9% of patients with CRS 3 (odd ratio [OR]=3.07; 95% CI=1.36–6.92) had no gross 
residual disease after IDS. However, there was no significant difference in the rate of optimal 
cytoreduction (residual tumor <1 cm) between patients with CRS 1–2 and CRS 3 tumors 
(p=0.785), optimal cytoreduction was achieved in 81.0% of and 83.0% of patients with CRS 
1–2 and CRS 3 disease, respectively.
Less than 6 months after last POAC, 83.3%, 26.3%, and 23.4% of patients with CRS 1, 2, 
and 3 had platinum-resistant diseases, respectively. There was a trend towards an inverse 
association between CRS and the frequency of platinum resistance (CRS 1–2, 31.8%; CRS 3, 
23.4%), although the difference was not statistically significant (p=0.336).
DISCUSSION
The CRS system was successfully used to stratify patients with respect to prognosis. In this 
study, we performed external validation of the CRS system in an independent cohort of tubo-
ovarian HGSC patients, of which the selection criteria for NAC, extent of IDS, surgical skill, 
and chemotherapy policies are different from those of the original cohort [5]. In our cohort, 
patients were homogenously selected for NAC and treated with minimization of confounding 
factors, such as the selection criteria for NAC, chemotherapy policies, and extent of surgery. 
We demonstrated that the CRS system was highly reproducible and exhibited prognostic 
significance and predictive value for tumor recurrence in an external cohort.
There is no recommended or agreed system for tumor regression grading for ovarian cancer 
treated with NAC. Therefore, there is unmet clinical need for a system to assess response to 
NAC. To date, 4 previous studies have documented tumor regression grading systems after 
NAC in advanced ovarian cancer [8-11]. Although these studies showed a correlation between 
response to NAC and survival, they did not validate their own criteria in an independent 
external cohort and did not assess reproducibility. Recently, Böhm et al. [5] proposed a 
3-tiered CRS system, validated its prognostic significance, and assessed its reproducibility 
in 2 independent cohorts. As suggested by Böhm et al. [5], the CRS system is easy to use in 
practice, cost-free, and reproducible. In this study, we assessed inter-observer reproducibility 
among 3 independent pathologists in our institution who trained on the 3-tiered CRS system 
using an electronically available website [12]. The parameters including Fleiss' kappa value, 
Kendall's coefficient of concordance, and the percentage of absolute agreement indicated 
high reproducibility of the CRS system.
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After the release of the CRS system, concerns were raised that the score is based on omental 
assessment instead of primary site assessment [13-15]. In tubo-ovarian HGSC, multiple 
intra-abdominal sites including the omentum are involved in addition to the primary site 
of origin. Considering the intratumor heterogeneity in genomic profiles according to the 
tumor location in advanced ovarian cancer [16], chemotherapy response is expected to vary 
between the location of primary and metastatic lesions. Böhm et al. [5] reported a significant 
correlation between outcome and omental CRS. However, they did not find any significant 
association between outcome and the adnexal CRS. Similarly, we found that adnexal CRS 
showed no significant association with outcome (p=0.317; Supplementary Fig. 1).
The CRS system has prognostic significance and can be used to stratify patients after NAC 
and IDS. In the validation cohort of Böhm et al. [5], there was no significant difference in 
PFS between CRS 1 and CRS 2. However, a prominent difference in PFS was found between 
CRS 2 and CRS 3. In this study, we observed a significant trend towards a positive association 
between CRS and PFS (p<0.001). We also found significant differences in PFS between CRS 
1 and CRS 2 (p<0.001) and CRS 2 and CRS 3 (p=0.046), respectively. While the outcomes of 
patients with CRS 2 tumors were similar to those of patients with CRS 1 in the study of Böhm 
et al. [5], we observed that outcomes of patients whose tumors exhibiting CRS 2 are similar 
to those of patients with CRS 3. In other words, the pattern of survival was different between 
Böhm et al. [5]'s validation cohort and that of ours. The median PFS was 12 months in the 
CRS 2 group from Böhm et al. [5]'s validation cohort and 15.7 months in the CRS 2 group 
from our cohort, whereas the median PFS of the CRS 3 group was approximately 18 months 
in both cohorts. The previous study showed a moderate but insignificant trend toward longer 
PFS in patients with complete versus incomplete debulking. In this study, residual disease 
after IDS was the most powerful prognostic factor on multivariate analysis and showed better 
PFS when complete debulking was achieved (no gross residual vs. any gross residual; adjusted 
HR=0.49; 95% CI=0.28–0.87). This might suggest that no gross residual disease after IDS 
overcomes the partial response (CRS 2) after NAC.
In order to determine the discriminatory performance of the CRS system, we calculated the 
c-index with 1,000 samples after bootstrapping. The c-index is similar to the area under the 
receiver operating characteristic (ROC) curve for logistic models and is measured on a scale 
ranging from 0.5 (no better than chance) to 1 (perfect prediction). Given that the c-index for 
the Cox model was above 0.700, CRS had a good performance in terms of discrimination.
This study has some limitations. First, it was limited by its retrospective nature and by small 
numbers in some score categories. The characteristics of patients whose tumors display a 
CRS of 1 and worse prognosis should be clarified to improve outcomes in this disease subset. 
Second, with increased use of NAC in recent years, our cohort is limited by the short follow-
up period. Further studies are necessary to identify outcomes such as OS with long-term 
follow-up databases.
In conclusion, we demonstrated that the CRS system has prognostic significance in an 
external cohort of tubo-ovarian HGSC patients. The CRS system is a reproducible prognostic 
tool for assessing NAC response in patients with HGSC to be externally validated. The 
addition of treatment response shows promise in improving survival estimates for HGSC 
patients treated with NAC.
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SUPPLEMENTARY MATERIAL
Supplementary Fig. 1
PFS according to the 3-tiered CRS system in the adnexa of tubo-ovarian HGSC patients 
receiving NAC (CRS 1–2 vs. CRS 3).
Click here to view
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